Label: BENZONATATE capsule

  • NDC Code(s): 51224-001-50, 51224-001-60, 51224-010-50, 51224-010-60
  • Packager: TAGI Pharma, Inc.
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: Abbreviated New Drug Application

Drug Label Information

Updated April 12, 2019

If you are a consumer or patient please visit this version.

  • DESCRIPTION

    Benzonatate, a non-narcotic oral antitussive agent, is 2, 5, 8, 11, 14, 17, 20, 23, 26-nonaoxaoctacosan-28-yl p-(butylamino) benzoate; with a molecular weight of 603.7.

    Benzonatate_Chem_Structure.jpg

    Each Benzonatate Capsules USP contains: Benzonatate, USP 100 mg or 200 mg.

    Benzonatate Capsules USP also contain: D&C Yellow 10, gelatin, glycerin, methylparaben, propylparaben and titanium dioxide.

  • CLINICAL PHARMACOLOGY

    Benzonatate Capsule acts peripherally by anesthetizing the stretch receptors located in the respiratory passages, lungs, and pleura by dampening their activity and thereby reducing the cough reflex at its source. It begins to act within 15 to 20 minutes and its effect lasts for 3 to 8 hours. Benzonatate Capsule has no inhibitory effect on the respiratory center in recommended dosage.

  • INDICATIONS AND USAGE

    Benzonatate Capsule is indicated for the symptomatic relief of cough.

  • CONTRAINDICATIONS

    Hypersensitivity to benzonatate or related compounds.

  • WARNINGS

    Hypersensitivity

    Severe hypersensitivity reactions (including bronchospasm, laryngospasm and cardiovascular collapse) have been reported which are possibly related to local anesthesia from sucking or chewing the capsule instead of swallowing it. Severe reactions have required intervention with vasopressor agents and supportive measures.

    Psychiatric Effects

    Isolated instances of bizarre behavior, including mental confusion and visual hallucinations, have also been reported in patients taking Benzonatate Capsule in combination with other prescribed drugs.

    Accidental Ingestion and Death in Children

    Keep Benzonatate Capsules out of reach of children. Accidental ingestion of Benzonatate Capsules resulting in death has been reported in children below age 10. Signs and symptoms of overdose have been reported within 15-20 minutes and death has been reported within one hour of ingestion. If accidental ingestion occurs, seek medical attention immediately (see OVERDOSAGE).

  • PRECAUTIONS

    Benzonatate is chemically related to anesthetic agents of the para-amino-benzoic acid class (e.g. procaine; tetracaine) and has been associated with adverse CNS effects possibly related to a prior sensitivity to related agents or interaction with concomitant medication.

    Information for Patients

    Swallow Benzonatate Capsules whole. Do not break, chew, dissolve, cut, or crush Benzonatate Capsules. Release of Benzonatate from the capsule in the mouth can produce a temporary local anesthesia of the oral mucosa and choking could occur. If numbness or tingling of the tongue, mouth, throat, or face occurs, refrain from oral ingestion of food or liquids until the numbness has resolved. If the symptoms worsen or persist, seek medical attention.

    Keep Benzonatate Capsules out of reach of children. Accidental ingestion resulting in death has been reported in children. Signs and symptoms of overdose have been reported within 15-20 minutes and death has been reported within one hour of ingestion. Signs and symptoms may include restlessness, tremors, convulsions, coma and cardiac arrest. If accidental ingestion occurs, seek medical attention immediately.

    Overdosage resulting in death may occur in adults.

    Do not exceed a single dose of 200 mg and a total daily dosage of 600 mg. If you miss a dose of Benzonatate Capsules, skip that dose and take the next dose at the next scheduled time. Do not take 2 doses of Benzonatate Capsules at one time.

    Usage in Pregnancy

    Pregnancy Category C.

    Animal reproduction studies have not been conducted with Benzonatate Capsules. It is also not known whether Benzonatate Capsules can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Benzonatate Capsules should be given to a pregnant woman only if clearly needed.

    Nursing Mothers

    It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk caution should be exercised when Benzonatate Capsule is administered to a nursing woman.

    Carcinogenesis, Mutagenesis, Impairment of Fertility

    Carcinogenicity, mutagenicity, and reproduction studies have not been conducted with Benzonatate Capsules.

    Pediatric Use

    Safety and effectiveness in children below the age of 10 have not been established. Accidental ingestion resulting in death has been reported in children below age 10. Keep out of reach of children.

  • ADVERSE REACTIONS

    Potential Adverse Reactions to Benzonatate Capsules may include:

    Hypersensitivity reactions including bronchospasm, laryngospasm, cardiovascular collapse possibly related to local anesthesia from chewing or sucking the capsule.

    CNS: sedation; headache; dizziness; mental confusion; visual hallucinations.

    GI: constipation; nausea; GI upset.

    Dermatologic: pruritus; skin eruptions.

    Other: nasal congestion; sensation of burning in the eyes; vague "chilly" sensation; numbness of the chest; hypersensitivity. Deliberate or accidental overdose has resulted in death, particularly in children.

  • OVERDOSAGE

    Intentional and unintentional overdose may result in death, particularly in children.

    The drug is chemically related to tetracaine and other topical anesthetics and shares various aspects of their pharmacology and toxicology. Drugs of this type are generally well absorbed after ingestion.

    Signs and Symptoms:

    The signs and symptoms of overdose of benzonatate have been reported within 15-20 minutes. If capsules are chewed or dissolved in the mouth, oropharyngeal anesthesia will develop rapidly, which may cause choking and airway compromise.

    CNS stimulation may cause restlessness and tremors which may proceed to clonic convulsions followed by profound CNS depression. Convulsions, coma, cerebral edema and cardiac arrest leading to death have been reported within 1 hour of ingestion.

    Treatment:

    In case of overdose, seek medical attention immediately. Evacuate gastric contents and administer copious amounts of activated charcoal slurry. Even in the conscious patient, cough and gag reflexes may be so depressed as to necessitate special attention to protection against aspiration of gastric contents and orally administered materials. Convulsions should be treated with a short-acting barbiturate given intravenously and carefully titrated for the smallest effective dosage. Intensive support of respiration and cardiovascular-renal function is an essential feature of the treatment of severe intoxication from overdosage. Do not use CNS stimulants.

  • DOSAGE AND ADMINISTRATION

    Adults and Children over 10 years of age: Usual dose is one 100 mg or 200 mg capsule three times a day as needed for cough. If necessary to control cough, up to 600 mg daily in three divided doses may be given. Benzonatate Capsules should be swallowed whole. Benzonatate Capsules are not to be broken, chewed, dissolved, cut or crushed.

  • HOW SUPPLIED

    Benzonatate Capsules USP , 100 mg are available as yellow, oval soft gelatin capsules with '1' imprinted in white ink.

    Bottles of 100: NDC 51224-010-50

    Bottles of 500: NDC 51224-010-60


    Benzonatate Capsules USP , 200 mg are available as yellow, oval soft gelatin capsules with '2' imprinted in white ink.

    Bottles of 100: NDC 51224-001-50

    Bottles of 500: NDC 51224-001-60

    Store at 20° to 25°C (68° to 77°F) excursions permitted between 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].

    PROTECT FROM LIGHT

  • SPL UNCLASSIFIED SECTION

    Rev. 2616

    Manufactured by:
    CSPC-NBP Pharmaceutical Co., Ltd.
    Shijiazhuang, Hebei, China, 052160

    Manufactured for:
    TAGI Pharma, Inc.
    South Beloit, IL 61080

  • PRINCIPAL DISPLAY PANEL - 100 mg Capsule Bottle Label

    NDC 51224-010-50

    Benzonatate
    Capsules USP

    100 mg

    Rx only

    100 CAPSULES

    CSPC®

    tagiPHARMA
    That's A Good Idea.

    PRINCIPAL DISPLAY PANEL - 100 mg Capsule Bottle Label
  • PRINCIPAL DISPLAY PANEL - 200 mg Capsule Bottle Label

    NDC 51224-001-50

    Benzonatate
    Capsules USP

    200 mg

    Rx only

    100 CAPSULES

    CSPC®

    tagiPHARMA
    That's A Good Idea.

    PRINCIPAL DISPLAY PANEL - 200 mg Capsule Bottle Label
  • INGREDIENTS AND APPEARANCE
    BENZONATATE 
    benzonatate capsule
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:51224-010
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    BENZONATATE (UNII: 5P4DHS6ENR) (BENZONATATE - UNII:5P4DHS6ENR) BENZONATATE100 mg
    Inactive Ingredients
    Ingredient NameStrength
    D&C YELLOW NO. 10 (UNII: 35SW5USQ3G)  
    GELATIN, UNSPECIFIED (UNII: 2G86QN327L)  
    GLYCERIN (UNII: PDC6A3C0OX)  
    METHYLPARABEN (UNII: A2I8C7HI9T)  
    PROPYLPARABEN (UNII: Z8IX2SC1OH)  
    TITANIUM DIOXIDE (UNII: 15FIX9V2JP)  
    Product Characteristics
    ColoryellowScoreno score
    ShapeOVALSize8mm
    FlavorImprint Code 1
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:51224-010-50100 in 1 BOTTLE; Type 0: Not a Combination Product09/07/2017
    2NDC:51224-010-60500 in 1 BOTTLE; Type 0: Not a Combination Product09/07/2017
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA20276509/07/2017
    BENZONATATE 
    benzonatate capsule
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:51224-001
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    BENZONATATE (UNII: 5P4DHS6ENR) (BENZONATATE - UNII:5P4DHS6ENR) BENZONATATE200 mg
    Inactive Ingredients
    Ingredient NameStrength
    D&C YELLOW NO. 10 (UNII: 35SW5USQ3G)  
    GELATIN, UNSPECIFIED (UNII: 2G86QN327L)  
    GLYCERIN (UNII: PDC6A3C0OX)  
    METHYLPARABEN (UNII: A2I8C7HI9T)  
    PROPYLPARABEN (UNII: Z8IX2SC1OH)  
    TITANIUM DIOXIDE (UNII: 15FIX9V2JP)  
    Product Characteristics
    ColoryellowScoreno score
    ShapeOVALSize11mm
    FlavorImprint Code N01
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:51224-001-50100 in 1 BOTTLE; Type 0: Not a Combination Product08/10/2015
    2NDC:51224-001-60500 in 1 BOTTLE; Type 0: Not a Combination Product08/10/2015
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA20276508/10/2015
    Labeler - TAGI Pharma, Inc. (963322560)
    Registrant - CSPC-NBP Pharmaceutical Co., Ltd. (723645870)
    Establishment
    NameAddressID/FEIBusiness Operations
    CSPC-NBP Pharmaceutical Co., Ltd.723645870manufacture(51224-010, 51224-001)